칸디다증 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측, 투여 경로별, 약제 유형별, 해부 유형별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Candidiasis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration, By Drug Type, By Anatomy Type, By End-User, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,174,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,546,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 10,976,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 칸디다증 치료제 시장은 2024년에는 33억 2,000만 달러로 평가되며, 예측 기간 중 CAGR은 6.22%를 기록하며, 2030년에는 47억 8,000만 달러에 달할 것으로 예측됩니다.

칸디다증은 주로 칸디다균에 의해 발생하는 진균 감염증으로 모든 연령층에서 건강관리에 대한 관심이 높아지고 있습니다. 구강 궤양, 질 감염, 식도 칸디다증, 침습성 칸디다증 등의 형태로 나타나며, HIV/AIDS 환자, 암 환자, 이식 환자 등 면역력이 약한 집단에서 높은 위험을 초래합니다. 항생제가 널리 사용되고 때로는 부적절하게 사용되는 것도 칸디다증의 확산에 일조하고 있습니다. 이에 따라 전 세계 치료제 시장에서는 효과적인 항진균 치료제에 대한 수요가 증가하고 있습니다. 환자군이 다양해지고 확대됨에 따라 혁신적인 표적 치료제에 대한 수요가 지속적으로 시장의 투자와 발전을 촉진하고 있습니다.

시장 개요
예측 기간	2026-2030
시장 규모 : 2024년	33억 2,000만 달러
시장 규모 : 2030년	47억 8,000만 달러
CAGR : 2025-2030년	6.22%
급성장 부문	경구
최대 시장	북미

시장 성장 촉진요인

칸디다증 증가

주요 시장 이슈

항진균제 내성

주요 시장 동향

항진균제 개발 및 기술 혁신

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 고객의 소리

제5장 세계의 칸디다증 치료제 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율·예측
  • 투여 경로별(주사, 연고, 경구)
  • 약제 유형별(Polyene, Azole, Echinocandin, 기타)
  • 해부 유형별(구강 칸디다증, 칸디다 질염, 피부 칸디다증, 침습성 칸디다증, 전신성 칸디다증)
  • 최종사용자별(병원·진료소, 약국, 기타)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 칸디다증 치료제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 칸디다증 치료제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 칸디다증 치료제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 칸디다증 치료제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 칸디다증 치료제 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 합병과 인수

제13장 세계의 칸디다증 치료제 시장 : SWOT 분석

제14장 경쟁 구도

• Bruker Corporation
• Astellas Pharma Inc.
• SCYNEXIS, Inc.
• NovaDigm Therapeutics
• Mycovia Pharmaceuticals, Inc.
• Cidara Therapeutics Inc.
• Pfizer Inc.
• Bayer AG
• Viatris Inc.

제14장 10 노바바이오틱스 리미티드

제15장 전략적 제안

제16장 조사회사 소개·면책사항

KSA

영문 목차

영문목차

The Global Candidiasis Therapeutics Market was valued at USD 3.32 billion in 2024 and is projected to reach USD 4.78 billion by 2030, registering a CAGR of 6.22% during the forecast period. Candidiasis, a fungal infection primarily caused by Candida species, remains a growing healthcare concern across all age groups. Manifesting in forms such as oral thrush, vaginal infections, esophageal candidiasis, and invasive candidiasis, it poses heightened risks for immunocompromised populations-including individuals with HIV/AIDS, cancer patients, and transplant recipients. The widespread and sometimes inappropriate use of antibiotics has further contributed to its rising prevalence. In response, the global therapeutics market is witnessing rising demand for effective antifungal treatments. With a diverse and expanding patient base, the need for innovative and targeted therapies continues to drive investment and advancements within the market.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 3.32 Billion
Market Size 2030	USD 4.78 Billion
CAGR 2025-2030	6.22%
Fastest Growing Segment	Oral
Largest Market	North America

Key Market Drivers

The Rising Incidence of Candidiasis

Candidiasis, primarily caused by Candida albicans and increasingly by drug-resistant species such as Candida auris, is on the rise globally. In 2024, the CDC reported more than 34,000 cases of candidemia in the United States alone, underscoring a significant year-over-year increase. The emergence of Candida auris, detected in over 40 countries, highlights the infection's expanding global impact. Key contributing factors include the widespread use of antibiotics, which disrupt healthy microbial balance, and a growing population of immunocompromised individuals-such as those undergoing chemotherapy, organ transplants, or living with HIV/AIDS. Aging demographics further heighten vulnerability to these infections. As the disease burden escalates, pharmaceutical and biotechnology companies are intensifying R&D efforts to develop advanced antifungal drugs. This momentum is reinforced by the need for therapeutics that are both more effective and capable of overcoming resistance, with many new treatments currently progressing through clinical trials.

Key Market Challenges

Antifungal Resistance

Antifungal resistance poses a major obstacle to candidiasis treatment worldwide. The increasing prevalence of multidrug-resistant strains, particularly Candida auris, has complicated the clinical landscape. In 2023 alone, over 2,400 cases of Candida auris were reported in the United States-nearly doubling from 2020 figures. Resistance to key antifungal classes such as azoles and echinocandins limits treatment options and increases reliance on less effective or more toxic alternatives. This trend is especially concerning in high-risk populations, including immunocompromised patients, where timely and successful intervention is crucial. The challenge underscores the need for continuous innovation and investment in resistance-mitigating therapies.

Key Market Trends

Antifungal Drug Development and Innovation

A leading trend in the Candidiasis Therapeutics Market is the sustained focus on novel antifungal drug development. The rise in drug-resistant infections has prompted pharmaceutical firms to prioritize research targeting resistant Candida species. Innovations include the development of next-generation antifungal agents as well as the exploration of combination therapies, which utilize multiple antifungal drugs to improve efficacy and reduce resistance risk. These advancements reflect a broader movement toward personalized, more effective treatment options, ensuring better outcomes for patients with complex or persistent infections.

Key Market Players

• Basilea Pharmaceutica Ltd
• Astellas Pharma Inc.
• SCYNEXIS, Inc.
• NovaDigm Therapeutics
• Mycovia Pharmaceuticals, Inc.
• Cidara Therapeutics Inc.
• Pfizer Inc.
• Bayer AG
• Viatris Inc.
• Novabiotics Limited

Report Scope:

In this report, the Global Candidiasis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Candidiasis Therapeutics Market, By Route of Administration:

• Injection
• Ointment
• Oral

Candidiasis Therapeutics Market, By Drug Type:

• Polyene
• Azole
• Echinocandin
• Other

Candidiasis Therapeutics Market, By Anatomy Type:

• Oral Candidiasis
• Vulvovaginal Candidiasis
• Cutaneous Candidiasis
• Invasive Candidiasis
• Systemic Candidiasis

Candidiasis Therapeutics Market, By End-User:

• Hospitals and Clinics
• Retail Pharmacies
• Other

Candidiasis Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Candidiasis Therapeutics Market.

Available Customizations:

Global Candidiasis Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Candidiasis Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Injection, Ointment, Oral)
  • 5.2.2. By Drug Type (Polyene, Azole, Echinocandin, Other)
  • 5.2.3. By Anatomy Type (Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis)
  • 5.2.4. By End-User (Hospitals and Clinics, Retail Pharmacies, Other)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Candidiasis Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration
  • 6.2.2. By Drug Type
  • 6.2.3. By Anatomy Type
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Candidiasis Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Drug Type
      • 6.3.1.2.3. By Anatomy Type
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Candidiasis Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Drug Type
      • 6.3.2.2.3. By Anatomy Type
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Candidiasis Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Drug Type
      • 6.3.3.2.3. By Anatomy Type
      • 6.3.3.2.4. By End-User

7. Europe Candidiasis Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration
  • 7.2.2. By Drug Type
  • 7.2.3. By Anatomy Type
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Candidiasis Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Drug Type
      • 7.3.1.2.3. By Anatomy Type
      • 7.3.1.2.4. By End-User
  • 7.3.2. United Kingdom Candidiasis Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Drug Type
      • 7.3.2.2.3. By Anatomy Type
      • 7.3.2.2.4. By End-User
  • 7.3.3. Italy Candidiasis Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Drug Type
      • 7.3.3.2.3. By Anatomy Type
      • 7.3.3.2.4. By End-User
  • 7.3.4. France Candidiasis Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Drug Type
      • 7.3.4.2.3. By Anatomy Type
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Candidiasis Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Drug Type
      • 7.3.5.2.3. By Anatomy Type
      • 7.3.5.2.4. By End-User

8. Asia-Pacific Candidiasis Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration
  • 8.2.2. By Drug Type
  • 8.2.3. By Anatomy Type
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Candidiasis Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Drug Type
      • 8.3.1.2.3. By Anatomy Type
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Candidiasis Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Drug Type
      • 8.3.2.2.3. By Anatomy Type
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Candidiasis Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Drug Type
      • 8.3.3.2.3. By Anatomy Type
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Candidiasis Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Drug Type
      • 8.3.4.2.3. By Anatomy Type
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Candidiasis Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Drug Type
      • 8.3.5.2.3. By Anatomy Type
      • 8.3.5.2.4. By End-User

9. South America Candidiasis Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration
  • 9.2.2. By Drug Type
  • 9.2.3. By Anatomy Type
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Candidiasis Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Drug Type
      • 9.3.1.2.3. By Anatomy Type
      • 9.3.1.2.4. By End-User
  • 9.3.2. Argentina Candidiasis Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Anatomy Type
      • 9.3.2.2.4. By End-User
  • 9.3.3. Colombia Candidiasis Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Drug Type
      • 9.3.3.2.3. By Anatomy Type
      • 9.3.3.2.4. By End-User

10. Middle East and Africa Candidiasis Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration
  • 10.2.2. By Drug Type
  • 10.2.3. By Anatomy Type
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Candidiasis Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Drug Type
      • 10.3.1.2.3. By Anatomy Type
      • 10.3.1.2.4. By End-User
  • 10.3.2. Saudi Arabia Candidiasis Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Drug Type
      • 10.3.2.2.3. By Anatomy Type
      • 10.3.2.2.4. By End-User
  • 10.3.3. UAE Candidiasis Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Drug Type
      • 10.3.3.2.3. By Anatomy Type
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Candidiasis Therapeutics Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Bruker Corporation
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Astellas Pharma Inc.
• 14.3. SCYNEXIS, Inc.
• 14.4. NovaDigm Therapeutics
• 14.5. Mycovia Pharmaceuticals, Inc.
• 14.6. Cidara Therapeutics Inc.
• 14.7. Pfizer Inc.
• 14.8. Bayer AG
• 14.9. Viatris Inc.

14.10 Novabiotics Limited

15. Strategic Recommendations

16.About Us & Disclaimer

관련자료